The role of probiotics in preventing necrotizing enterocolitis
Necrotizing enterocolitis (NEC) is one of the most serious gastrointestinal diseases affecting premature and very-low-birth-weight infants. It can progress from feeding intolerance and intestinal inflammation to bowel necrosis, perforation, sepsis, surgery, and death. Survivors may face prolonged hospitalization, poor growth, neurodevelopmental impairment, or intestinal failure.
Because the immature intestine is influenced by microbial colonization, nutrition, immunity, and barrier function, probiotics have received sustained attention in neonatal medicine. These live microorganisms may help establish a healthier intestinal ecosystem, although their benefits depend on the strain, dose, preparation, and population receiving them.
The subject fits naturally within the scientific priorities represented by the FAOPS 2020 congress site, which brought together perinatal and neonatal specialists for research and clinical discussion. Interest in probiotic supplementation has continued even as neonatal teams have refined feeding protocols, infection prevention, and decision-making for infants at the highest risk of NEC.
Why premature infants are vulnerable to NEC
NEC occurs most often in infants born very prematurely or with very low birth weight. Their intestinal barrier is structurally and functionally immature, while immune regulation remains underdeveloped. Reduced motility, unstable circulation, exposure to antibiotics, delayed enteral feeding, and dependence on intensive care interventions can further disturb the gut environment.
The intestinal microbiome is another important factor. Healthy microbial communities interact with the intestinal lining and help regulate immune development. In contrast, premature infants may develop dysbiosis, characterized by reduced microbial diversity and an increased presence of potentially harmful organisms. This imbalance may contribute to exaggerated inflammation when the bowel encounters feeding or infection-related stress.
Human milk, especially the mother’s own milk, remains a central protective strategy. It supplies immunological components, growth factors, and bioactive substances that support intestinal maturation. Donor milk may be used when a mother’s milk is unavailable, while standardized feeding advancement and careful management of hemodynamic instability also influence NEC risk.
How beneficial bacteria may support intestinal protection
Probiotics are commonly defined as live microorganisms that provide a health benefit when administered in adequate amounts. In neonatal care, the organisms studied most often include strains from the Bifidobacterium and Lactobacillus genera, as well as selected combinations. Their effects should not be generalized across all products because different strains can behave differently in the intestine.
Several biological mechanisms may explain a protective effect. Probiotics can compete with pathogenic organisms for nutrients and attachment sites, produce antimicrobial substances, and alter the acidity of the intestinal environment. They may also strengthen tight junctions between intestinal cells, helping reduce the permeability that permits bacterial products to cross the gut barrier.
Immune modulation is another proposed pathway. Certain probiotic strains may reduce excessive inflammatory signaling while supporting more balanced mucosal immunity. They can influence the production of short-chain fatty acids and other metabolites that nourish intestinal cells. These mechanisms are plausible, but laboratory findings do not automatically predict the results of clinical supplementation in fragile newborns.
The practical aim is therefore broader than adding bacteria to the gut. A successful prevention strategy would support intestinal maturation while limiting inflammation and invasive infection. Probiotics may contribute to that strategy alongside human milk, cautious feeding progression, antibiotic stewardship, and careful monitoring for early clinical deterioration.
What clinical studies indicate
Randomized trials and systematic reviews have frequently reported that probiotic supplementation is associated with a lower incidence of severe NEC, particularly Bell stage II or higher disease. Some analyses also suggest reductions in all-cause mortality and late-onset sepsis, although the strength of these findings varies according to the included studies and the probiotic preparations used.
The evidence is less consistent for extremely preterm infants, those below 1,000 grams at birth, and infants with major medical complications. Many trials include relatively broad preterm populations, making it difficult to determine whether the same benefit applies to the smallest or most unstable babies. Differences in feeding practices, baseline NEC rates, strain combinations, and product quality create additional uncertainty.
| Evidence area | What research generally suggests | Important limitation |
|---|---|---|
| Severe NEC | A possible reduction in Bell stage II or higher disease | Benefit varies by strain and study population |
| Mortality | Some reviews report lower all-cause mortality | Results are not uniform across trials |
| Late-onset sepsis | Potential reduction in selected preterm groups | Definitions and organisms differ between studies |
| Growth and feeding tolerance | Possible improvement in feed advancement or tolerance | Outcomes are less consistently measured |
| Extremely low birth weight infants | Evidence remains particularly uncertain | The most fragile infants are often underrepresented |
| Product safety | Serious probiotic infection appears uncommon | Contamination, misidentification, and quality control remain concerns |
These findings support careful consideration rather than universal assumptions. A product labeled as containing a particular species may not have the same clinical effect as a well-characterized strain tested in a neonatal trial. Clinicians must evaluate the totality of evidence, local outcomes, product regulation, and the condition of each infant.
Choosing infants and timing supplementation
Eligibility policies differ among neonatal intensive care units. Some centers consider probiotics for infants born before a defined gestational age or below a specified birth weight once enteral feeds have begun. Others limit use to infants receiving human milk or wait until clinical stability and feeding tolerance are established.
Timing matters because an infant with severe circulatory instability, suspected intestinal ischemia, or early signs of NEC may not be an appropriate candidate. Probiotics are intended for prevention, not for treatment of established disease. Abdominal distension, bloody stools, apnea, temperature instability, metabolic acidosis, or concerning radiographic findings require immediate clinical assessment rather than continued routine supplementation.
Administration practices should be standardized. Staff need clear instructions for storage, preparation, dosing, documentation, and handling around antibiotics. If a product is administered through feeding tubes, the process should minimize contamination and preserve accurate identification of the infant and preparation.
Feeding context also deserves attention. Human milk may provide complementary microbial and immunological support, while formula-only feeding, prolonged antibiotic exposure, and delayed enteral nutrition may alter the expected response. These factors do not automatically rule out probiotic use, but they should be incorporated into individualized risk assessment and outcome evaluation.
Safety and product quality in the neonatal unit
The main safety concern is probiotic-associated sepsis, in which the administered organism enters the bloodstream or another normally sterile site. Reported cases are uncommon, yet the consequences can be serious. Risk may be higher in infants with central venous catheters, severe immunological compromise, intestinal barrier injury, or critical illness.
Product quality is equally important. Some supplements marketed for general use may lack the manufacturing controls expected for pharmaceutical products. Concerns include inaccurate strain identification, variable viable counts, contamination with unwanted organisms, and differences between the product studied in a clinical trial and the product available in practice.
A neonatal unit considering supplementation should establish governance before implementation. This includes review by neonatology, microbiology, pharmacy, infection prevention, nursing, and institutional leadership. The unit should define eligibility, exclusion criteria, consent procedures, adverse-event reporting, and a process for stopping supplementation when NEC or sepsis is suspected.
Ongoing surveillance can make use more responsible. Teams can track NEC stage, surgery, mortality, late-onset bloodstream infection, feeding milestones, probiotic exposure, and any organism recovered from a sterile-site culture. If a probiotic-related infection is suspected, the product should be retained for investigation and the relevant infection-control procedures activated promptly.
Translating research into bedside practice
Implementation requires more than purchasing a supplement. Clinicians need to understand the evidence behind the selected strains and communicate its limitations to families. Parents should be told that probiotics may reduce the risk of severe NEC in some preterm populations, but they do not eliminate the disease and are not a substitute for human milk, clinical observation, or timely treatment.
Education and simulation can support safe delivery. Teams can rehearse recognition of early NEC, escalation of abdominal findings, specimen collection, antibiotic decisions, and communication with families. Resources on simulation in perinatal emergencies are relevant because prevention depends on coordinated action when an infant’s condition changes rapidly.
A local protocol should be reviewed whenever new evidence, regulatory guidance, or safety information becomes available. It should also account for regional differences in available products, laboratory capacity, antimicrobial resistance, human milk access, and baseline NEC rates. A policy that works in one unit may require substantial adaptation elsewhere.
Practical safeguards for probiotic use
- Select a product with clearly identified strains, reliable manufacturing, and documented neonatal evidence.
- Define eligibility, dosing, storage, administration, and discontinuation criteria in a written protocol.
- Prioritize mother’s own milk and donor human milk when available, with careful feeding advancement.
- Train staff to recognize NEC, probiotic-associated infection, and product-handling problems.
- Monitor clinical outcomes and adverse events through regular multidisciplinary review.
The most defensible approach treats probiotics as one component of a broader NEC prevention bundle. That bundle may include antenatal corticosteroids, appropriate respiratory and circulatory care, human milk feeding, standardized nutrition, infection prevention, antibiotic stewardship, and rapid response to early warning signs.
Further research should compare individual strains and combinations, include extremely premature infants, assess long-term neurodevelopment and growth, and use consistent definitions of NEC and sepsis. Trials also need transparent reporting of product manufacture and viable organism counts. These details are essential for converting promising biological theory into dependable neonatal care.
Clinicians, researchers, and families can help advance safer practice by reviewing the evidence, strengthening local protocols, and reporting outcomes consistently. Use the available scientific and educational resources to support a multidisciplinary discussion about whether probiotic supplementation belongs in your unit’s NEC prevention program.
